Table 5.
Clinical validity EORTC QLQ-C30 and QLQ-BR23 Amharic version in women with breast cancer in Ethiopia (n = 146)
| Quality of life score: mean(SD) | ||||
|---|---|---|---|---|
| EORTC-QLQ-C30 | Baseline | End of 1st CTb cycle | p-value | |
| Overall QoL | Global Health status | 57.36(20.09) | 41.72(19.24) | 0.000 |
| Physical | 68.63(26.06) | 51.00(23.70) | 0.000 | |
| Role | 52.74(38.85) | 23.74(31.37) | 0.000 | |
| Functional scales | Emotional | 80.02(22.60) | 67.81(25.14) | 0.000 |
| Cognitive | 86.41(19.96) | 77.39(26.31) | 0.000 | |
| Social | 74.88(30.59) | 58.22(33.11) | 0.000 | |
| Fatigue | 28.69(30.40) | 72.07(26.10) | 0.000 | |
| Symptoms scales | Nausea and Vomiting | 3.31(11.84) | 53.53(34.19) | 0.000 |
| Pain | 32.53(30.53) | 42.00(33.11) | 0.001 | |
| Dyspnea | 19.40(29.75) | 28.76(29.97) | 0.003 | |
| Insomnia | 27.85(34.58) | 35.61(37.88) | 0.024 | |
| Single items | Appetite loss | 17.80(29.59) | 71.23(31.22) | 0.000 |
| Constipation | 10.27(21.99) | 22.83(31.74) | 0.000 | |
| Diarrhea | 2.74(12.07) | 16.89(30.38) | 0.000 | |
| Financial problem | 61.18(36.72) | 65.52(33.77) | 0.000 | |
| EORTC-QLQ-BR23 | ||||
| Functional scales | Body Image | 72.54(42.45) | 72.60(27.24) | 0.985 |
| Sexual Functioning | 21.11(36.95) | 12.21(28.72) | 0.004 | |
| Therapya side effects | 12.88(15.08) | 50.71(19.70) | 0.000 | |
| Symptoms scale | Breast symptoms | 22.48(22.34) | 17.63(19.94) | 0.000 |
| Arm symptoms | 26.03(26.08) | 18.79(23.18) | 0.000 | |
| Single items | Future perspectives | 69.63(33.43) | 63.69(35.21) | 0.041 |
| Sexual Enjoyment | 72.91(32.70) | 70.83(34.15) | 0.817 | |
aSystemic therapy side effects
bAfter three weeks, on 21st day of the CT (Chemotherapy) or on the first day of 2nd cycle CT.
SD Standard Deviation, QoL Quality of Life